The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
First-in-human trial of a poly(ADP)-ribose polymerase (PARP) inhibitor MK-4827 in advanced cancer patients with antitumor activity in BRCA-deficient tumors and sporadic ovarian cancers (soc).
W. R. Schelman
No relevant relationships to disclose
S. K. Sandhu
No relevant relationships to disclose
V. Moreno Garcia
No relevant relationships to disclose
G. Wilding
No relevant relationships to disclose
L. Sun
Employment or Leadership Position - Merck
C. Toniatti
Employment or Leadership Position - Merck Sharp & Dohme
Stock Ownership - Merck Sharp & Dohme
M. Stroh
Employment or Leadership Position - Merck Sharp & Dohme
Stock Ownership - Merck Sharp & Dohme
N. Kreischer
Employment or Leadership Position - Merck Sharp & Dohme
Stock Ownership - Merck Sharp & Dohme
C. L. Carpenter
Employment or Leadership Position - Merck
Stock Ownership - Merck Sharp & Dohme
L. R. Molife
No relevant relationships to disclose
S. B. Kaye
No relevant relationships to disclose
J. S. De Bono
No relevant relationships to disclose
R. M. Wenham
No relevant relationships to disclose